Liquid Biopsy Market Analysis By Product Type, By Circulating Biomarker Type, By Clinical Application, By Application, By End-User, By Region and Forecast To 2027

Liquid Biopsy: Introduction

Liquid biopsy is a minimally invasive test involving the sampling and examination of non-solid biological tissue, blood, in particular, to detect molecular biomarkers in the body. The test is a simple, non-invasive substitute for surgical biopsies and enables doctors to diagnose life-threatening diseases like cancer at an initial stage. Liquid biopsies for cancer help identify cancerous cells in a tumor that circulate in the blood.

Various healthcare, pathological laboratories, and research institutes are increasingly conducting liquid biopsy tests to analyze the molecular aspects of cancer, gather important information on a patient’s cancer profile, and determine effective therapies to improve the cancer patient’s survival rate. The rapid process of liquid biopsy generally involves blood sampling, extracting nucleic acids from blood plasma, and elevating molecular targets to analyze the defined biomarkers effectively.

The technique is mainly intended for the diagnosis and monitoring of severe diseases like cancer and also excludes the need for highly invasive or expensive procedures. It aids in the regular tracking of tumors and mutations in a more efficient way over a specific duration of time.

Moreover, liquid biopsy is beneficial for monitoring the relapse of a disease long after its treatment. Thus, it offers a wide array of advantages over traditional biopsies, such as early cancer detection, access to tumor genome, characterization of new lesions, drug and therapeutic development for cancer, reduced costs, and, most essentially, patient comfort.

Global Liquid Biopsy Market: Dynamics

In this section of the global liquid biopsy market report, the most prominent factors that could either propel or limit the global market growth over the forecast period have been summarized. The report focuses on the significant market growth parameters, key drivers, opportunities, challenges, and threats, alongside observing the industry’s ongoing trends.

The global liquid biopsy market is foreseen to gain significant traction in the forthcoming years, due to a slew of factors, such as the surging prevalence of cancer worldwide, increasing awareness about and preference for minimally invasive procedures, personalized medicine development spurring the adoption of liquid biopsy tests, favorable government initiatives, increasing availability of funding for liquid biopsy R&D, and major advantages of liquid biopsy tests over solid tissue biopsies.

The rise in pre-screening programs for cancer diagnosis is another factor expected to offer growth prospects for the liquid biopsy market. However, there are certain potential hindrances to market growth, such as increasing alternatives to liquid biopsies and unclear reimbursement policies and regulations.

COVID-19 Impact on the Global Liquid Biopsy Market:

The latest research report on the global liquid biopsy market expounds on the current market scenario that has observed an economic downturn due to the devastating effects of the COVID-19 pandemic. Apart from taking millions of lives, the pandemic has led to major disruptions to the global liquid biopsy market demand and supply chains. However, our team of analysts speculates that the market will soon regain momentum in the post-COVID era. The overwhelming changes in this industry vertical and the aftereffects of the COVID-19 outbreak have been assessed in the report.

Global Liquid Biopsy Market: Geographical Outlook

In 2017, North America dominated the global liquid biopsy market, with the largest share. However, the Asia Pacific regional segment is predicted to demonstrate the highest growth rate during the estimated period of 2020–2027. Factors likely to trigger regional growth include the rising prevalence of cancer, burgeoning demand for non-invasive treatment options, and evolving healthcare infrastructure. India, one of the leading countries in the region, is anticipated to contribute to the regional market growth in the near future.

The leading regions encompassed in the report are as follows:

· North America

· Europe

· Asia Pacific

· Latin America

· Middle East & Africa

Global Liquid Biopsy Market: Competitive Analysis

The report offers a detailed study of the leading companies’ profiles, underscoring the fundamental strategic initiatives employed by them, such as collaborations, joint ventures, mergers & acquisitions, new business deals, and technological upgradation to reach an advantageous market position.

The key contenders profiled in the report include:

· F. Hoffmann-La Roche AG

· Fraunhofer-Gesellschaft

· Janssen Diagnostics, LLC

· Biocept, Inc.

· Myriad Genetics

· GRAIL

· Bio-Rad Laboratories Inc.

· Exosome Sciences

· Trovagene Inc.

· Guardant Health Inc.

· MDX Health SA

· Horizon Discovery

· Diagnologix

· Qiagen

· Cynvenio

· CyoTrack

Key Report Highlights:

1. The latest report presents an in-depth quantitative analysis of the current liquid biopsy market scenario from the historical period of 2017–2018 to the forecast duration of 2019–2027.

2. The market estimations offered by our analysts are based on the exhaustive investigation of the key developments taking place in the industry.

3. The developmental strategies adopted by the top players have been discussed to throw light on the intensely competitive terrain of the market.

4. The report’s profound geographical analysis enables the reader to comprehend the regional market dominance and strategic business planning.

Global Liquid Biopsy Market Segmentation

Product Type

· Assay kits

· Services

· Instruments

Circulating Biomarker

· Circulating Tumor Cells (CTCs)

· Cell-Free DNA (cfDNA)

· Circulating Tumor DNA (ctDNA)

· Extracellular Vesicles (EVs)

· Others (including circulating RNA (cfRNA and ctRNA) and cell-free protein biomarkers)

Clinical Application

· Early Cancer Screening

· Treatment Monitoring

· Therapy Selection

· Recurrence Monitoring Orthopedics

Application

· Oncology

· Breast Cancer

· Lung Cancer

· Colorectal Cancer

· Melanoma Cancer

· Prostate Cancer

· Other Cancer Types

Non-Cancer Applications

· End-Use

· Hospitals & Physician Laboratories

· Academic & Research Centers

· Reference Laboratories

· Others